Table 2 Characteristics of the included studies in the review
Authors (year) | Participants | Study Design | Country | Inclusion Criteria | Exclusion Criteria | Outcome assessed | Follow-up | PEDro Score |
|---|---|---|---|---|---|---|---|---|
Dongmei et al. (2011) [19] | n = 24 (14: SCA and 10: MSA-C) Age: 46 years old | Non-randomized clinical trial | China | SCA | Cardiopulmonary, renal and hepatic dysfunction, or systemic infection. | ICARS and ADL | 6 and 15 months | 5 Points |
Jin et al. (2013) [20] | n = 16 Age: 39.9 ± 10.2 years old | Open label uncontrolled clinic trial | China | SCA1, SCA2 or SCA3, age 16–65 years old. | Cardiopulmonary, renal and hepatic dysfunction, or systemic infection; tumor markers; blood pressure > 180/110 mmHg; pregnancy or breastfeeding. | BBS and ICARS | 3, 6 and 12 months | 6 Points |
Tsai et al. (2017) [21] | n = 7 Age: 48.85 ± 14.75 years old | Pilot open label Phase I / IIa clinical trial | Taiwan | SCA 3 or MSA-C varying 10–20 on SARA | Another trial with cell therapy less than 30 days, positive pregnancy test. | SARA, SOT, MRI and F-FDG PET | 12 months | 5 Points |